UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  July 9, 2007

NEUROMETRIX, INC.

(Exact name of registrant as specified in its charter)


Delaware

 

000-50856

 

04-3308180

(State or other jurisdiction of

 

Commission file number

 

(I.R.S. Employer

incorporation or organization)

 

 

 

Identification No.)

 

62 Fourth Avenue

Waltham, Massachusetts  02451

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (781) 890-9989

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 




 

Item 5.02            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 9, 2007, Dr. Jonathan T. Lord notified NeuroMetrix, Inc. (the “Company”) that he was resigning as a director of the Company for personal reasons effective as of the filing of this Periodic Report on Form 8-K.  Dr. Lord had no disagreements with the Company on any matter relating to the Company’s operations, policies or practices.

The Board of Directors of the Company thanks Dr. Lord for his dedicated service and valued contributions to the Company.

 

2




 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

NEUROMETRIX, INC.

 

 

 

 

 

Dated: July 12, 2007

 

By:

 

/s/ Shai N. Gozani, M.D., Ph.D.

 

 

 

 

Shai N. Gozani, M.D., Ph.D.

 

 

 

 

Chairman, President and Chief Executive Officer

 

3